Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Phase Ib/II multi-arm study of combinations of novel agents in R/R AML

Nicholas Short • 1 Dec 2020
ASH 2020
Acute Myeloid Leukemia Leukemia Antibodies Avelumab Azacitidine Gemtuzumab ozogamicin Glasdegib Venetoclax

Nicholas Short, MD, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the findings of a Phase Ib/II multi-arm study (NCT03390296) which investigated various combinations of novel agents in relapsed/refractory acute myeloid leukemia (AML). The trial had 5 arms: azacitidine (aza) + venetoclax (VEN) + gemtuzumab ozogamicin (GO; a anti-CD33 monoclonal antibody), aza + VEN + avelumab (PD-1R mAb), AZA + avelumab + GO, OX40 agonist monoclonal antibody, and glasdegib (SMO inhibitor) + GO. All 3 arms testing novel triplet combinations demonstrated safety and efficacy and thus, accrual to his cohorts will continue. The cohorts treated with OX40 agonist and glasdegib + GO showed no responses, although the patient numbers were small. This trial design testing multiple novel combinations may be a more rapid method of identifying possible feasible regimens as an increasing number of therapeutics become available. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Consulting fees: Takeda Oncology, AstraZeneca
Research funding: Takeda Oncology, Astellas Pharma Inc.
Honoraria: Amgen

More from Nicholas Short

Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
2:31
Azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML: long-term follow-up
Nicholas Short • 6 Dec 2025
What is on the horizon for the treatment of B-cell and T-cell ALL?
1:37
What is on the horizon for the treatment of B-cell and T-cell ALL?
Nicholas Short • 6 Dec 2025
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
2:17
Predictors of outcomes with and without alloSCT after first salvage therapy for R/R B-ALL
Nicholas Short • 6 Dec 2025
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
2:20
Comparing PCR for BCR::ABL1 versus NGS-based MRD in Ph+ ALL: which method is superior?
Nicholas Short • 6 Dec 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals